The low CD19+/CD3− B cell count is due to the fact that all three samples used for the leukocyte subset analysis were from patients with multiple myeloma, for whom a statistically significant decrease of the percentage of total CD19+ cells is observed compared with healthy controls [29]. The gene discussed is CD19; the disease is plasma cell myeloma.